Webinar | March 25, 2022

How To Scale Up The Production Of Therapeutic Viral Vectors For Gene Therapy Applications

With multiple products approved and commercialized, gene therapy has now gone beyond proof of concept and entered mainstream healthcare. This success urgently requires work on manufacturing processes to ensure that gene therapies are widely available to all that need them. Pall’s Acceleratorâ„  process development services help our customers develop reproducible and scalable processes for viral vector manufacturing in order to meet clinical and commercial market demand in very short timelines. We will outline how we work with our customers in providing this service, and present case studies of Adeno-Associated Virus (AAV) and Lentivirus (LV) production using adherent and suspension cell culture. Furthermore, we will present how we can also help our customers build their production facility with virtual reality through our Accelerator Vision platform.

VIEW THE WEBINAR!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online